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Impact of Medical Treatment on the Outcome of Patients
After Aneurysmal Subarachnoid Hemorrhage
Frederique H Vermeij, MD; Djo Hasan, MD, PhD;
Henk W.C. Bijvoet, MD; Cees J.J. Avezaat, MD, PhD
Background and Purpose—The rationale behind early aneurysm surgery in patients with subarachnoid hemorrhage (SAH)
is the prevention of rebleeding as early as possible after SAH. In addition, by clipping the aneurysm as early as possible,
one can apply treatment for cerebral ischemia more vigorously (induced hypertension) without the risk of rebleeding.
Hypervolemic hemodilution is now a well-accepted treatment for delayed cerebral ischemia. We compared the
prospectively collected clinical data and outcome of patients admitted to the intensive care unit in the period 1977 to
1982 with those of patients admitted in the period 1989 to 1992 to measure the effect of the change in medical
management procedures on patients admitted in our hospital with SAH.
Methods—We studied 348 patients admitted within 72 hours after aneurysmal SAH. Patients with negative angiography
results and those in whom death appeared imminent on admission were excluded. The first group (group A) consisted
of 176 consecutive patients admitted from 1977 through 1982. Maximum daily fluid intake was 1.5 to 2 L.
Hyponatremia was treated with fluid restriction (,1 L/24 h). Antihypertensive treatment with diuretic agents was given
if diastolic blood pressure was .110 mm Hg. Patients in the second group (172 consecutive patients; group B) were
admitted from 1989 through 1992. Daily fluid intake was at least 3 L, unless cardiac failure occurred. Diuretic agents
and antihypertensive medications were avoided. Cerebral ischemia was treated with vigorous plasma volume expansion
under intermittent monitoring of pulmonary wedge pressure, cardiac output, and arterial blood pressure, aiming for a
hematocrit of 0.29 to 0.33. Aneurysm surgery was planned for day 12.
Results—Patients admitted in group B had less favorable characteristics for the development of cerebral ischemia and for
good outcome when compared with patients in group A. Despite this, we found a significant decrease in the frequency
of delayed cerebral ischemia in patients of group B treated with tranexamic acid (P50.00005 by log rank test) and
significantly improved outcomes among patients with delayed cerebral ischemia (P50.006 by x2 test) and among
patients with deterioration from hydrocephalus (P50.001 by x2 test). This resulted in a significant improvement of the
overall outcome of patients in group B when compared with those in group A (P50.006 by x2 test). The major cause
of death in group B was rebleeding (P50.011 by x2 test).
Conclusions—We conclude that the outcome in our patients with aneurysmal SAH was improved but that rebleeding
remains a major cause of death. Patient outcome can be further improved if we can increase the efficacy of preventive
measures against rebleeding by performing early aneurysm surgery. (Stroke. 1998;29:924-930.)
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Treatment of SAH is aimed at prevention of rebleedingthrough clipping of the aneurysm and at prevention and
treatment of cerebral ischemia and hydrocephalus. Many
articles have been published on the management of patients
after SAH from a ruptured intracranial aneurysm, and almost
all reported either results of a study concerning drug effica-
cy1,2 or results of studies concerning early versus delayed
aneurysm surgery. More and more neurosurgeons rely on
early aneurysm surgery rather than delayed surgery for the
prevention of rebleeding after aneurysmal SAH.3–12 The
rationale behind early aneurysm surgery is that by clipping
the aneurysm as early as possible, one can apply treatment for
cerebral ischemia more vigorously (for example, induced
hypertension) without the risk of a rebleed. However, in most
studies early aneurysm surgery failed to improve outcome
when compared with delayed surgery, probably because of an
increase in the frequency of cerebral ischemia.5–12 However,
two studies reported a beneficial effect of early surgery.3,4 In
contrast to the previous studies,5–12 in these two studies3,4
prophylactic hypervolemic therapy was applied during the
postoperative period. In addition, the favorable effects of
hypervolemic hemodilution on cerebral perfusion have been
reported in experimental studies13,14 and on cerebral ischemia
in patients with SAH.15–21 Until recently, early aneurysm
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surgery was not performed in our center. On the other hand,
medical treatment of patients with SAH was gradually chang-
ing: increase in daily fluid intake, immediate treatment of
hydrocephalus and high CSF pressure, introduction of treat-
ment of cerebral ischemia with hypervolemic hemodilution,
and prescription of nimodipine. Therefore, we have the
opportunity to compare the prospectively collected clinical
data and outcome of patients admitted to the ICU in the
period 1977 to 1982 with those of patients admitted in the
period 1989 to 1992. We did not restrict our study to patients
who were fit enough to undergo aneurysm surgery, and our
objective was to measure the effect of the change in the whole
package of medical management in all patients admitted to
our hospital with SAH.
Subjects and Methods
From November 1977 through December 1992 we studied 779
consecutive patients with SAH who were admitted to the ICU. All
patients had clinical features of SAH and were admitted within 72
hours after the bleed. SAH was confirmed by CT, revealing
distribution of subarachnoid blood compatible with aneurysmal
hemorrhage, or when the CT scan revealed no blood, by spectro-
photometric analysis of the CSF. If the patient had a motor score of
3 on the GCS and negative pupillary reflexes on admission, or if the
motor score on admission was #2 and the level of consciousness did
not improve within 72 hours after admission, the patient was
excluded from the study (80 patients). In addition, patients with
negative angiograms (39 patients) were not entered in the study.
Between 1977 and 1982, medical treatment remained unchanged.
From 1983 until 1989, medical treatment of patients with SAH was
gradually changing (for example, increase in daily fluid intake,
immediate treatment of hydrocephalus, treatment of cerebral ische-
mia with hypervolemic hemodilution, and prescription of nimodip-
ine). From 1989 onward, medical treatment remained grossly un-
changed. Therefore, from the remaining 660 patients, we included
those admitted between 1977 and 1982 (n5176) and between 1989
and 1992 (n5172).
CT scanning was performed on admission (initial CT scan). The
amount of blood in each of the 10 cisterns was graded, on a scale of
0 to 3, separately for each of the 10 cisterns (maximum sum score of
30).22 A sum score of 18 or higher was regarded as a “high cisternal
blood score.” Similarly, intraventricular blood was graded separately
for each of the four ventricles (maximum sum score of 12). Because
a ventricular score of 1 reflects sedimentation of red blood cells in
the ventricle, we considered relevant only a score of .1 for at least
one of the four ventricles, and we referred only to this as “presence
of intraventricular blood.”
All patients were kept in the ICU during the first 28 days or until
death or aneurysm surgery. The level of consciousness was assessed
by means of the 14-point GCS.23 When deterioration of the patient’s
clinical condition occurred, physical examination (and CT scan if
possible) was repeated. Hydrocephalus detected by CT on admission
was referred to as “hydrocephalus on the initial CT.” Hydrocephalus
is defined as the bicaudate index (width of the frontal horns at the
level of the foramina of Monro, divided by the corresponding
diameter of the brain) on the CT exceeding the 95th percentile for
age. The upper limits were as follows: ,36 years of age, 0.16; 36 to
45 years, 0.17; 46 to 55 years, 0.18; 56 to 65 years, 0.19; 66 to 75
years, 0.20; and 76 to 85 years, 0.21.24,25 Clinical events occurring
during the observation period were defined as follows: (1) deterio-
ration from hydrocephalus was defined as deterioration of the level
of consciousness with no detectable cause other than hydrocephalus
confirmed by a repeat CT; (2) probable delayed ischemia was
gradual development of focal neurological signs with or without
deterioration of the level of consciousness, without confirmation by
CT or autopsy; (3) definite cerebral ischemia was defined as
development of focal neurological signs or deterioration of the level
of consciousness, or both, with CT or autopsy evidence of cerebral
infarction; (4) probable rebleeding was sudden deterioration of the
level of consciousness and death, without CT confirmation or if
autopsy was refused; and (5) definite rebleeding was defined as
sudden deterioration of the level of consciousness, with or without
focal signs, with an increase in the amount of blood on a repeat CT
or at autopsy when compared with a previous CT scan. In the
analysis we counted definite and probable cerebral ischemia as
cerebral ischemia and definite and probable rebleeding as rebleeding.
In the first period (November 1977 through December 1982,
group A), the patients (n5176) were enrolled in a multicenter trial
(centers in the United Kingdom and the Netherlands were involved)
on the effect of tranexamic acid.26 These patients were randomized
for tranexamic acid: 89 patients received placebo treatment (group
A1) and 87 patients were treated with tranexamic acid for 28 days or
until aneurysm surgery (6 g/d intravenously in the first week and 4
g/d intravenously or 6 g/d orally in the next 3 weeks, group A2).
Maximum daily fluid intake was between 1.5 and 2 L. Hyponatremia
was treated with fluid restriction (,1 L/24 h) under the assumption,
now proved incorrect, that hyponatremia was caused by the syn-
drome of inappropriate secretion of antidiuretic hormone.27–30 We did
not apply preventive measures against cerebral ischemia or hyper-
volemic hemodilution. Antihypertensive treatment with diuretic
agents was given if diastolic blood pressure was .110 mm Hg.
External ventricular drainage was performed when the patient
deteriorated from hydrocephalus, we were reluctant to insert a
ventricular catheter when the clinical condition of the patient
deteriorated mildly. We preferred external drainage to internal shunt
in the first 2 weeks after SAH.
From 1989 through 1992 all 172 patients (group B) were treated
with tranexamic acid and nimodipine (6360 mg/d orally or 2 mg/h
intravenously) during the first 21 days or until their operations.1,2 As
preventive measure for cerebral ischemia, daily fluid intake was at
least 3 L unless cardiac failure occurred.27–30 Fludrocortisone (230.2
mg/d) was administered as a preventive measure against hyponatre-
mia. When hyponatremia did occur, sodium chloride was adminis-
tered. Diuretic agents were avoided. Antihypertensive medication
was not given unless the patient was on this medication on
admission. In the absence of a hematoma with mass effect and if
blood did not completely fill the third and fourth ventricles, we
treated hydrocephalus by means of serial lumbar puncture or external
lumbar CSF drainage. If hydrocephalus persisted or if a contraindi-
cation for lumbar puncture existed, an external ventricular catheter
was inserted. We preferred external CSF drainage to internal shunt
during the first 2 weeks after the bleed for obvious reasons. When
cerebral ischemia occurred, it was treated with vigorous plasma
volume expansion under intermittent monitoring of pulmonary
wedge pressure, cardiac output, pulmonary arterial pressure, sys-
temic vascular resistance (by means of a Swan-Ganz catheter), and
systemic arterial blood pressure, aiming at a hematocrit of 0.29 to
0.33.13–21
Angiography was performed depending on the patients’ clinical
condition. An aneurysm was confirmed either by angiography or by
autopsy in 130 of 176 (74%) patients in group A and in 142 of 172
(83%) patients in group B (Table 1). In the remaining 76 of the 348
(22%) patients aneurysm rupture was considered highly probable
because of the extravasation of blood in the frontal interhemispheric,
suprasellar, or Sylvian cisterns without evidence of other causes of
SAH. Aneurysm clipping was planned for day 12 in all groups. All
surviving patients had a follow-up for at least 3 months after SAH.
They visited the outpatient clinic or were interviewed by means of a
written questionnaire. Outcome was assessed by means of the
5-point GOS.31 We reduced the GOS to three categories: dead (GOS
Selected Abbreviations and Acronyms
CSF 5 cerebrospinal fluid
GCS 5 Glasgow Coma Scale
GOS 5 Glasgow Outcome Scale
SAH 5 subarachnoid hemorrhage
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score of 1), dependent (GOS score of 2 or 3), and independent (GOS
score of 4 or 5).
Differences in frequency of entry characteristics, outcome, and
cause of death between groups were assessed with the two-sided
x2 test. Because patients with a GCS score of 13 (14-point GCS)
were either drowsy or disorientated without a decrease in the
motor score, we chose a GCS score of 12 as the breakpoint for the
analysis (Figure 1). Differences in first-occurring cerebral events
(deterioration from hydrocephalus, delayed cerebral ischemia,
and rebleeding) and differences in time-dependent medical treat-
ments (aneurysm surgery, external CSF drainage, internal CSF
shunt) between groups were analyzed by plotting Kaplan-Meier
survivor function estimates against time. Univariate analysis,
stratified by one variable at a time, was performed with the log
rank test.32,33 We stress that in the analysis of outcome at 3 months
(as presented in Figure 3), calculations of the proportion of
patients with first-occurring cerebral complication were done
with simple arithmetic. On the other hand, in the Kaplan-Meier
plots as presented in Figure 1, calculations of the proportion of
patients with first-occurring cerebral complication were per-
formed by means of the estimation of the survivor function.32 One
must bear in mind that there is a difference in the results of the
calculated proportion of patients between these two methods due
to, among others, the censoring mechanism of survival analysis.34
Results
Characteristics of all patients are presented in Table 1.
Patients in group A exhibited less cisternal (P,0.000001
by x2 test) and less ventricular blood on the initial CT scan
compared with patients in group B. The proportion of
patients with an aneurysm of the posterior circulation was
significantly higher in group B than in group A. Hydro-
cephalus on the initial CT was found in a significantly
greater proportion in patients of group B than in group A.
The proportion of patients free from deterioration from
hydrocephalus was lower in group B than in group A1
(P,0.000001 by log rank test) and group A2 (P50.00003
by log rank test; Figure 1). In addition, the proportion of
patients free from deterioration from hydrocephalus was
lower in group A2 than group A1 (P50.0044 by log rank
test; Figure 1). In patients treated with tranexamic acid,
cerebral ischemia developed less often in group B com-
pared with group A2 (P50.00005 by log rank test; Figure
1). The difference in the development of cerebral ischemia
between group A1 and group A2 was not statistically
significant. The proportion of patients free from rebleeding
was lower in group A2 (P50.0009 by log rank test) and
group B (P50.0049 by log rank test) than in group A1
(Figure 1). Aneurysm surgery was performed more fre-
quently in group B than in group A1 (P50.0290 by log
rank test) and group A2 (P50.000005 by log rank test;
Figure 1). The proportion of patients free from aneurysm
surgery in group A1 was lower than that in group A2
(P50.0341 by log rank test; Figure 1). The proportions of
patients who received CSF drainage and internal ventric-
ular shunting are summarized in Figure 2. External CSF
drainage was performed more frequently in group B than
group A1 (P50.0016 by log rank test) and group A2
(P50.0006 by log rank test). No differences in the fre-
quency of internal ventricular shunts between groups were
seen.
Figure 3 shows the outcome at 3 months of all 348
patients. In patients without complications, outcome be-
tween group A and group B was not significantly different.
Mortality in patients in whom rebleeding occurred as a
first cerebral complication was slightly higher in group B
than group A, but the difference was not statistically
significant. Outcome in patients with deterioration from
hydrocephalus in group B was significantly better when
compared with that of patients in group A (P50.001 by x2
test). This difference is caused by a decrease in the
proportion of patients with dependent outcome and a
decrease in the mortality of patients with deterioration
from hydrocephalus in group B. Among patients with
cerebral ischemia, outcome was also significantly better in








No. % No. %
Sex
Male 68 39 57 33
Female 108 61 115 67
Mean age, y 52.1 51.5
#40 38 22 42 24
41–60 80 45 81 47
.60 58 33 49 28
Lost of consciousness at ictus, n 88 52 101 59
Duration of loss of consciousness at ictus, h
,1 47 53 61 60
1–8 21 24 23 23
9–24 5 6 4 4
25–72 12 14 0 0
Unknown 3 3 13 13
Sum score of Glasgow Coma Scale
#12 61 35 65 38
.12 115 65 107 62
Sum score of cisternal blood on initial CT
,18 153 87* 71 41.5
18–30 23 13* 100 58.0
Not graded 0 0 1 0.5
Ventricular blood, n
Present 43 24† 60 35
Absent 133 75† 110 64
Not graded 0 0 2 1
Aneurysm confirmed, n 130 74 142 83
Carotid artery 51 39‡ 35 25
Middle cerebral artery 19 15‡ 37 26
Anterior cerebral artery 52 40‡ 46 32
Posterior circulation 8 6‡ 23 16
Unknown (multiple aneurysm) 0 0‡ 1 1
Hydrocephalus on initial CT, n 35 20§ 57 33
n indicates number of patients. Significantly different from number than
patients in group A by x2-test: *x2578.165, P,0.000001; †x254.88,
P50.027; ‡x2516.891, P50.002; and §x2510.685, P50.001.
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group B than in group A (P50.006 by x2 test). This change
was caused by a decrease in the mortality of patients with
cerebral ischemia in group B. As a consequence, overall
outcome in group B was significantly better than that in
group A (P50.006 by x2 test).
In group A, both cerebral ischemia and rebleeding are
major causes of death (Table 2). In group B, cerebral
ischemia as cause of death occurred significantly less often
than in group A (P50.033 by x2 test). In contrast,
rebleeding as cause of death occurred significantly more
often in group B than in group A (P50.011 by x2 test).
Discussion
Patients in group B had more unfavorable prognostic factors
for cerebral ischemia (such as amount of cisternal blood on
the initial CT scan and the presence of ventricular blood) and
for good outcome (amount of cisternal blood and aneurysm of
the posterior circulation) than patients in group A (Table 1).
This is probably the result of a change in the referral behavior
of consultants in the region of our hospital. Apparently, more
patients with severe bleeding were referred to our hospital
from 1989 through 1992 (group B).
The high frequency of hydrocephalus demonstrated on
the admission CT scan and the high frequency of deterio-
ration from hydrocephalus in group B compared with those
in group A are probably the result of the higher frequency
of patients with high amounts of cisternal blood and a
higher frequency of the presence of ventricular blood in
group B (Figure 1). Both are prognostic factors for the
development of deterioration from hydrocephalus.35,36 Im-
provement of outcome in patients with hydrocephalus is
obviously the result of a change in the treatment of
hydrocephalus. In group A patients, we were reluctant to
insert a ventricular catheter when the clinical condition of
the patient deteriorated mildly. In contrast, we switched to
lumbar puncture and lumbar external drainage in group B,
and we initiated external CSF drainage more frequently
than in group A (Figure 3). Despite this, the need for
permanent internal shunting was not different between
group A2 and group B; both groups were treated with
tranexamic acid (Figure 3), a risk factor for deterioration
from hydrocephalus.35,36 It is known that external CSF
drainage may precipitate rebleeding.37,38 Despite this, there
was a significant decrease in the proportion of death and
Figure 2. Plots of Kaplan-Meier sur-
vival function estimates against time
on CSF drainage after the initial SAH
in 348 patients.
Figure 1. Plots of Kaplan-Meier sur-
vival function estimates against time
on the first-occurring cerebral compli-
cation after the initial SAH and on
aneurysm surgery in 348 patients.
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dependent patients in those patients with deterioration
from hydrocephalus in group B compared with similar
patients in group A, which resulted from our change in
strategy (P50.006 by x2 test; Figure 3).
Daily fluid intake in group B was much higher than that
in group A, and fluid restriction in hyponatremic patients
was omitted in group B in contrast to group A. In addition,
cerebral ischemia in group B was treated with hypervole-
mic hemodilution (aiming for a hematocrit of about 0.30)
under invasive monitoring of cardiac output, pulmonary
wedge pressure, pulmonary arterial pressure, and systemic
blood pressure. The idea was to optimize the low shear-
rate viscosity of the whole blood and to ensure adequate
cerebral perfusion pressure in order to restore the regional
cerebral blood flow in perfusion areas beyond the vaso-
spastic vessels.13–21 Although patients in group B were
treated with tranexamic acid, and despite the fact that this
treatment may precipitate cerebral ischemia in patients
with aneurysmal SAH, the occurrence of cerebral ischemia
in group B was significantly lower than that in group A2
(P50.00005 by log rank test) and slightly lower than that
of group A1 (Figure 2). Moreover, outcome at 3 months for
patients in group B was significantly better than that of
group A (Figure 3). The decrease in the occurrence of
cerebral ischemia in group B can probably be attributed to
the high daily fluid intake and the well-accepted beneficial
effect of hypervolemic hemodilution.13–21
Although the characteristics of the patients in group B
were worse than those of group A patients with regard to
the prognostic factors for the occurrence of cerebral
ischemia and bad outcome,39 – 44 the decrease in the fre-
quency and mortality rate of cerebral ischemia and the
improved results of hydrocephalus treatment led to an
increase in the proportion of patients fit for aneurysm
surgery at the end of the second week after the initial
bleed. As a result, overall outcome improved significantly
(Figure 3). However, rebleeding became a more frequent
cause of death in group B when compared with group A
(Table 2).
An article on a study performed from 1977 through 1981
reported good outcome in patients with SAH (46%),
similar to that in group A.45 Other studies, performed after
1985, have reported a similar proportion (56%) of good
outcome when compared with group B.5 Others have
reported a better result (71% to 87% good outcome) than
that in group B.43,46 –50 Patients included in the latter study
were those admitted to a neurosurgical unit. Consequently,
most of these patients were in a fair clinical condition, fit
for surgery. This probably explains the difference in
outcome when compared with group B. Improved out-
come, when corrected for prognostic factors for bad
outcome,39,40,42,43 is probably the result of improved man-
agement: operative technique, timing of aneurysm surgery,
or improved medical treatment. In a retrospective study, it
was reported that outcome improved after treatment with
hypervolemic hemodilution was initiated.48 On the other
hand, nonrandomized trials on the timing of aneurysm
surgery failed to show a significant difference between
early and delayed surgery. Although early surgery lowered
Figure 3. Bar graph showing the
outcome at 3 months in 348 patients
with SAH, stratified by first-occurring
cerebral complication after SAH.









No. % No. %
Initial bleed 1 1 4 7
Cerebral ischemia 22 26 6* 10
Rebleeding 31 37 35† 59
Hydrocephalus 6 7 0 0
Other‡ 25 29 14 24
Significantly different from number than patients in group A by x2 test:
*x254.53, P50.033; †x256.43, P50.011.
‡Other causes of death were pulmonary embolism, neurogenic pulmonary
edema, septic shock, and operative complications.
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the rebleeding rate significantly, this beneficial effect was
negated by a substantial increase in postoperative cerebral
ischemia.5–12 In contrast, a prospectively performed ran-
domized study3 reported an improved outcome after early
surgery (0 to 3 days) compared with that after delayed
surgery (.8 days after SAH) (96% [25 of 26 patients]
versus 77% [22 of 28 patients]). However, the difference
did not reach statistical significance because of the small
numbers of patients included.
We conclude that outcome in our patients with aneu-
rysmal SAH was improved in the course of time as the
result of a change in the medical treatment strategy of
these patients, which led to an improved outcome in
patients with cerebral ischemia and those with deteriora-
tion from hydrocephalus. On the other hand, rebleeding
remains a major cause of death. A further improvement in
the outcome of these patients is possible if we can increase
the efficacy of preventive measures against rebleeding by
performing early aneurysm surgery.
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